

CURRICULUM VITAE

Curtis L Triplitt

GENERAL INFORMATION

PERSONAL DATA:

Date of Preparation: 06/29/2022

Address: Texas Diabetes Institute
701 South Zarzamora
MS 10-5
San Antonio, TX 78207

Phone Number: (210) 358-7228

Fax Number: (210) 358-7235

Email Address: triplitt@uthscsa.edu

EDUCATION:

<u>Year</u>	<u>Degree</u>	<u>Discipline</u>	<u>Institution/Location</u>
1995	PharmD	Clinical Pharmacy	UTHSCSA/University of Texas at Austin, San Antonio, TX
1993	BS	Pharmacy	University of Iowa, Iowa City, IA

TRAINING:

Residency

<u>Year</u>	<u>Discipline</u>	<u>Institution/Location</u>
1995-1996	Primary Care/ Ambulatory Care	William S. Middleton VA Hospital, Madison, WI, United States

ACADEMIC APPOINTMENTS:

09/2022-	Professor/Clinical	University of Texas Health at San Antonio, San Antonio, TX
09/2013 – 9/2022	Associate Professor / Clinical	University of Texas Health at San Antonio, San Antonio, TX
09/2004 - 09/2013	Assistant Professor/Clinical	University of Texas Health Science Center at San Antonio, Department of Medicine, San Antonio, TX

01/1998 - Present	Assistant Professor/Clinical	University of Texas at Austin, College of Pharmacy, Department of Pharmacotherapy Research & Graduate Training, San Antonio, TX
09/1997 - 09/2004	Instructor	University of Texas Health Science Center at San Antonio, Department of Medicine, San Antonio, TX
08/1997 - 08/1998	Assistant Professor of Pharmacy Practice	Butler University, Department of College of Pharmacy and Health Sciences, Indianapolis, IN

NON-ACADEMIC APPOINTMENTS:

01/1997 - Present	Research Pharmacist	Texas Diabetes Institute, San Antonio, TX
-------------------	---------------------	---

Details: Active researcher in the field of metabolism, type 2 diabetes mellitus, and hypertension. Administrator responsible for budget, research pharmacist, and involved with clinical care of patients with diabetes mellitus in conjunction with endocrinologist. Active in education of post-doctorate fellows from Department of Medicine, Division of Diabetes, UTHSCSA, and University of Texas College of Pharmacy Students and Residents.

CERTIFICATION AND LICENSURE:

Board Certification

<u>Description/Agency</u>	<u>Status</u>	<u>Date Acquired</u>	<u>Number</u>	<u>Expiration</u>
Board Certified Pharmacotherapy Specialist - Board of Pharmaceutical Specialty(voluntary additional board certification for pharmacists)	Certified	12/1998	n/a	12/2005

Certification

<u>Description/Agency</u>	<u>Status</u>	<u>Date Acquired</u>	<u>Number</u>	<u>Expiration</u>
Certified Diabetes Educator - National Certification Board of Diabetes Educators	Certified	06/1998	2041-0592	12/2024

License to Practice

<u>Description/Agency</u>	<u>Status</u>	<u>Date Acquired</u>	<u>Number</u>	<u>Expiration</u>
----------------------------------	----------------------	-----------------------------	----------------------	--------------------------

Registered Pharmacist - Board Certified 08/1993 34167 n/a
of Pharmacy, Texas

HONORS AND AWARDS:

- 06/2020 Fellow of the Association of Diabetes Care and Education Specialists: One of less than 100 diabetes educators voted to become a Fellow of this Professional Diabetes Educator Focused Organization. ADCES is involved with patient education care standards, research opportunities for educators, prevention, care, and cure initiatives for diabetes mellitus. Awarded based on sustained service to the organization through committee work, diabetes education initiatives, and presentations to and at ADCES meetings
- 06/2017 Wall of Honor- Texas Diabetes Institute: Award of Excellence in Diabetes given by University Health System representing sustained contributions and representation for local, state, and national entities. Award was given for sustained research contributions Names of Recipients, for areas of excellence such as community service, leadership, and research are located on the "Wall of Honor," on the second floor of the Texas Diabetes Institute, UHS
- 08/2008 Arlyn W. Kloesel Award-Preceptor of the Year, University of Texas: Awarded by University of Texas at Austin College of Pharmacy and Alumni Association. Chosen as 4th year pharmacist preceptor of the year out of more than 700 preceptors.
- 10/2006 Recognition Award- Texas Diabetes Council: Presented by Chair, Texas Diabetes Council, Texas Department of State Health Services. Work accomplished on coordination and contributions to the 1st "Diabetes Tool Kit" available to providers and educators of the State of Texas as a free, comprehensive resource for health care professionals to educate people with diabetes.
- 08/2005 Diabetes Excellence Award-Texas Diabetes Council: Award by Texas Diabetes Council, Texas Department of State Health Services for Leadership in Standards of Care for Diabetes in the State of Texas. Awarded for the creation of diabetes standards of care and algorithms, which have been adopted or emulated by several other state diabetes councils around the nation.
- 01/2005 Marquis's Who's Who in Medicine and Healthcare: Who's Who- from 2005-2006

PROFESSIONAL DEVELOPMENT:

Clinical

<u>Date</u>	<u>Description</u>	<u>C.E. Units/Hours</u>
08/09/2019 - 08/12/2019	Association of Diabetes Care and Education Specialists Annual Meeting, Attend Annual Meeting Every Year to increase knowledge within diabetes education realm	20.00 / 24.00
10/01/2018 - 10/05/2018	European Association for the Study of Diabetes (EASD), Annual Meeting	0.00 / 40.00
08/17/2018 - 08/20/2018	American Association of Diabetes	22.00 / 32.00

	Educators, Attend Annual Meeting Every Year to increase knowledge within diabetes education realm	
08/04/2017 - 08/07/2017	American Association of Diabetes Educators, Attend Annual Meeting Every Year to increase knowledge within diabetes education realm	23.00 / 32.00
09/12/2016 - 09/16/2016	European Association for the Study of Diabetes (EASD), Annual Meeting	0.00 / 40.00
08/12/2016 - 08/15/2016	American Association of Diabetes Educators, Attend Annual Meeting Every Year to increase knowledge within diabetes education realm	22.00 / 32.00
08/05/2015 - 08/08/2015	American Association of Diabetes Educators, Attend Annual Meeting Every Year to increase knowledge within diabetes education realm	23.00 / 32.00
08/06/2014 - 08/09/2014	American Association of Diabetes Educators, Attend Annual Meeting Every Year to increase knowledge within diabetes education realm	24.00 / 32.00
08/09/2013 - 08/12/2013	American Association of Diabetes Educators, Attend Annual Meeting Every Year to increase knowledge within diabetes education realm	25.00 / 32.00

Research

<u>Date</u>	<u>Description</u>	<u>C.E. Units/Hours</u>
06/12/2020 - 06/16/2020	American Diabetes Association Annual Meeting, (virtual)	20.00 / 40.00
06/07/2019 - 06/11/2019	American Diabetes Association Annual Meeting, Attend Annual Meeting every year to better be able to contribute to Dept of Medicine/Div. of Diabetes, interact with other fellow researchers, and obtain information on the latest research in diabetes field.	27.00 / 40.00
06/22/2018 - 06/26/2018	American Diabetes Association Annual Meeting	24.00 / 40.00
06/05/2015 - 06/09/2015	American Diabetes Association Annual Meeting	28.00 / 40.00
06/13/2014 - 06/17/2014	American Diabetes Association Annual Meeting	27.00 / 40.00
06/21/2013 - 06/25/2013	American Diabetes Association Annual Meeting	22.00 / 40.00
06/01/1998 - 06/30/2012	American Diabetes Association Annual Meeting, Attend Annual Meeting every year to better be able to contribute to Dept of Medicine/Div. of Diabetes, interact with other fellow researchers, and obtain information on the latest research in diabetes	24.00 / 32.00

field.

TEACHING**COURSE BASED TEACHING:**

<u>Date</u>	<u>Course Name</u>	<u>Level</u>	<u>Role</u>
12/2012 - 12/2012	Diabetes Mellitus	Undergraduate	Lecturer

Preparation Hrs: 25, Student Contact Hrs: 2 ; University of Pittsburgh College of Pharmacy: 2 hours of videotaped lecture on pathophysiology and etiology of diabetes mellitus. Used for University of Pittsburgh COP students and allowed to be used at other College of Pharmacies around the country that may not have the resources to provide such an in-depth diabetes mellitus offering.

03/2010 - 03/2010	Endocrine, Women's Health, and Hematologic Disorders PHA 5593	Undergraduate/Graduate	Lecturer
-------------------	---	------------------------	----------

Preparation Hrs: 30, Student Contact Hrs: 5 ; University of Florida at Gainesville, College of Pharmacy 3 hours of videotaped lecture for Non-traditional PharmD Program for practicing pharmacists: Pharmacotherapy of type 1 diabetes mellitus, Pharmacotherapy of type 2 diabetes mellitus, Case studies in diabetes, Web based didactic lectures, followed by answering questions posed by students on the topics via web on multiple occasions

09/2007 - 09/2007	Endocrine, Women's Health, and Hematologic Disorders PHA 5593	Undergraduate/Graduate	Lecturer
-------------------	---	------------------------	----------

Preparation Hrs: 30, Student Contact Hrs: 5 ; University of Florida at Gainesville, College of Pharmacy 3 hours of lecture for Non-traditional PharmD Program for practicing pharmacists: Pharmacotherapy of type 1 diabetes mellitus, Pharmacotherapy of type 2 diabetes mellitus, Case studies in diabetes, Web based didactic lectures, followed by answering questions posed by students on the topics via web on multiple occasions

01/2002 - 01/2002	Injection Technique	Undergraduate	Lecturer
-------------------	---------------------	---------------	----------

Preparation Hrs: 10, Student Contact Hrs: 4

01/2001 - 01/2004	Peripheral Vascular and Diabetic Physical Exam	Undergraduate	Lecturer
-------------------	--	---------------	----------

Preparation Hrs: 10, Student Contact Hrs: 4 ; Teaching 3rd year pharmacy students physical assessment for peripheral exam and diabetic foot exam.

02/1997 - 03/1997	1855 Advanced Therapeutics	Undergraduate	Lecturer
-------------------	----------------------------	---------------	----------

Preparation Hrs: 20, Student Contact Hrs: 2 ; Butler University. Physician Assistant Students

11/1996 - 11/1996 A.P. 313 Therapeutics-Adrenal Undergraduate Lecturer

Preparation Hrs: 20, Student Contact Hrs: 2 ; Butler University. Physician Assistant Courses

OTHER TEACHING:

Post Graduate Rotation Supervision

<u>Date</u>	<u>Description</u>	<u>Institution</u>	<u># Students</u>
08/1998 - Present	Pharmacy Residents	UTHSCSA/UT College of Pharmacy/Armed Forces/University Health System	30

PGY1 and PGY2 Pharmacy Residents: pharmacy residents in general year of training or specialty training. Provide Diabetes Clinical Care and Education for all aspects regarding diabetes mellitus. PGY1 and PGY2 residents follow a standardized curriculum: Discussions-2-3 hours each week of rotation 1. Diabetes diagnosis and classification 2. Pathophysiology of diabetes 3. Pharmacological and non-pharmacological management of diabetes 4. HTN, Nephropathy and diabetes 5. Lipids and diabetes 6. Neuropathy and diabetes Residents see DM patients in clinic-first shadowing preceptor or endocrinologist, then on own and check out to attending endocrinologist Additionally attend Div. of Diabetes Journal Club, present 1-2 Journal Clubs to preceptor and staff, attend Medicine Grand Rounds Since 2012: 10 residents (1-2/ year)

Post-Doctoral Student Supervision

<u>Date</u>	<u>Description</u>	<u>Institution</u>	<u># Students</u>
12/2012 - Present	Post-Doctoral Division of Diabetes Fellow Supervision	Texas Diabetes Institute-Clinical Research Center	16

Oversee procedures that post-doctoral fellows assist in helping. Fellows are assigned specific studies to assist coordinators and help with many aspects of study conduct. Help mentor the fellows to: orient them to procedures and how to conduct, where to find supplies, DEXA, indirect calorimetry, medications, proper study related visits and procedural issues, data collection, data analysis, data publication, IRB liaison, key people to conduct research, administrator in collaboration with Medical Director All are MD's with main mentor of Dr. Ralph DeFronzo 1. Garduno-Garcia, J. 2012 2. Daniele G, 2011-13 3. Eldor R, 2012-2014 4. Upala S. 2012-2014 5. Alatrach M 2013-2021 6. Hamidi V 2014-2015 7. Martinez R 2014-2016 8. Al Jobori H. 2015-2017 9. Teresawa T. 2016-2020 10. Qin Y 2016 to present 11. Ali A 2016 to 2019 12. Honka H 2017-2019 13. Laichuthai N. 2017-2019 14. Eletrabi M 2017 to 2021 15. Baskoy G 2019-present 16. Barkhordarian, M. 2021-present

Rotation Student Supervision

<u>Date</u>	<u>Description</u>	<u>Institution</u>	<u># Students</u>
--------------------	---------------------------	---------------------------	--------------------------

08/1998 - Present PharmD candidates- 4th Year UTHSCSA/UT College of Pharmacy/University of Incarnate Word 40

All rotations at the Texas Diabetes Institute, University Health System Each student is full time with me, the preceptor, for 6 weeks. A. We have a set curriculum where the student performs 2 journal clubs in 6 weeks, and a 2-3 hour discussion each week including: -Diagnosis and classification of diabetes -Pathophysiology of diabetes -HTN and Nephropathy in diabetes -Lipid management in diabetes -Neuropathy and treatment -Pharmacological management of diabetes B. Students attend diabetes clinic- assess DM patients with preceptor, then on own assess DM patients and we all "check out" to attending endocrinologist. C. Students attend Div. of Diabetes journal club and Medicine Grand Rounds during rotation 40 students since 2001 Additional Students from: Incarnate Word College of Pharmacy, Boise State College of Pharmacy, University of Florida College of Pharmacy From: 2012-present (University of Texas Students listed by name) 1. Bhakta T. 2. Meyer S. UT 3. Rek J UT 4. Tripp K UT 5. Kim S UT 6. Maheshwri R UT 7. Johnson J UT 8. Kuehn G UT 9. Hang K UT 10. Ji J UT 11. Kruse C UT 12. Rodahl B UT 13. Boise State, Idaho- 1 student Non-traditional PharmD 14. U of Florida-Gainesville- 1 student Non-traditional PharmD 15. Incarnate Word, San Antonio- 1 student PGY4

RESEARCH

EXPERTISE:

Metabolic/Diabetes Insulin Sensitivity Procedures - Performing euglycemic hyperinsulinemic clamp research procedure for assessment of insulin sensitivity. Performing hyperglycemic clamp for assessment of pancreatic beta-cell and insulin secretion function. Performance of OGTT's for beta-cell sensitivity, insulin secretion, and insulin sensitivity. Interpretation of data from metabolic/insulin sensitivity procedures.

PUBLICATIONS: (indicates Peer Reviewed)**

Abstract

- * Solis-Herrera C, Qin Y, Honka H, Moody A, Clarke GE, Triplitt CL, Cersosimo E, DeFronzo RA. Effect of hyperketonemia on cardiac efficiency in patients with heart failure and type 2 diabetes. 2022 June p. 175-OR ([Diabetes](#))
- * Barkhordarian M, Triplitt CL, Solis-Herrera C, Adams JM, DeFronzo RA, Cersosimo E. Mechanisms of dapagliflozin to reduce intraglomerular pressure in patients with type 2 diabetes. 2022 June p. 857-P ([Diabetes](#))
- * Chavez Velazquez AO, Ali E, Merovci A, Agyin C, Terasawa T Abdul-Ghani M, Triplitt C, Cersosimo E, DeFronzo RA. Effect of Pharmacologic (EPIC) therapy on insulin sensitivity and beta-cell function in prediabetes (preDM). 2022 June p. 644-P ([Diabetes](#))
- * 1. Ezrokhi M, Cincotta A, Cersosimo E, Adams J, Alatrach M, Agyin C, Triplitt CL, Cominos N, DeFronzo RA. Bromocriptine-QR (BQR) ameliorates a pro-oxidative stress/proinflammatory (POS/PI) monocyte phenotype in poorly controlled T2DM subjects 2020 Jul. p. 1070-P. ([Diabetes](#)).
- * 2. Alatrach M, Agyin C, Nitchakarn L, Lavrynenko O, Adams J, Abdul-Ghani M, Triplitt CL, DeFronzo RA, Cersosimo E. Glucose kinetics during oral glucose challenge following administration of exenatide and dapagliflozin alone and in combination in type 2 diabetes 2020 Jul. p. 1136-P. ([Diabetes](#)).

- * 3. Chamarthi B, Cersosimo E, Adams J, Alatrach M, Agyin C, Triplitt CL, Ezrokhi M, Luo S, Duvallet E, Cincotta A, DeFronzo RA. Bromocriptine-QR (BQR) therapy reduces elevated sympathetic nervous system activity (SNSA) and oxidative stress (OS) in type 2 diabetes (T2D) subjects whose dysglycemia is poorly controlled on GLP-1 receptor agonist (GLP-1RA) 2019 Jul. p. 1166-P. (Diabetes).

- * 4. Solis-Herrera C, Alatrach M, Agyin M, Honka H Patel R, Triplitt CL, Adams J, Gastaldelli A, Abdul-Ghani M, Cersosimo E, DeFronzo RA. The increase in endogenous glucose production with SGLT2 inhibition is unchanged by renal

denervation but highly correlates to urinary glucose excretion 2019 Jul. p. 155-LB. ([Diabetes](#)).

- * 5. Qin Y, Adams J, Martinez R, Pino A, Al Jobori H, Triplitt CL, DeFronzo RA, Cersosimo E. Clinical parameters, fuel oxidation, and glucose kinetics in T2D patients treated with dapagliflozin plus saxagliptin combination 2018 Jul. p. 1192-P. ([Diabetes](#)).
- * 6. Terasawa T, Triplitt CL, Adams J, Cersosimo E, DeFronzo RA, Chavez Velaquez A. Differential beta-cell response to intravenous exenatide (EXEN) and arginine (ARG) in prediabetic subjects with impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) 2018 Jul. p. 1810-P. ([Diabetes](#)).
- * 7. DeFronzo R, Martinez R, Jabori H, Triplitt CL, Cersosimo E. Liraglutide fails to offset the rise in hepatic glucose production (HGP) see with SGLT2i treatment 2017 Jul. p. 1075-P. ([Diabetes](#)).
- * 8. Solis-Herrera C, Alatrach M, Agyin C, Triplitt CL, Adams J, Gastaldelli A, Abdul-Ghani A, Cersosimo E, DeFronzo RA. Endogenous glucose production increase with SGLT2 inhibition is unchanged by denervation in renal transplant patients 2017 Jul. p. 162-LB. ([Diabetes](#)).
- * 9. Martinez R, Al-Gburi K, Al Jobori H, Adams J, Abdul-Ghani M, Triplitt CL, DeFronzo RA, Cersosimo E. Effect of combination SGLT2i and GLP-1RA therapy on glycemic control, body weight, and beta-cell function in type 2 diabetic (T2D) subjects 2017 Jul. p. 167-LB. ([Diabetes](#)).
- * 10. Al Jobori, Daniele G, Martinez R, Abdul-Ghani A, Adams J, Triplitt CL, Cersosimo E, DeFronzo R. Empagliflozin improves beta-cell function measured with the hyperglycemic clamp in T2DM 2016 Jul. p. 1097-P. ([Diabetes](#); vol. 64).
- * 11. Agyin C, Alatrach M, Adams J, Ganapathy V, Chandamohan S, Caga-Anan C, Philips P, Triplitt CL, DeFronzo R, Cersosimo E. Glucose lowering and vascular protective mechanisms of dopamine agonist therapy in patients with type 2 diabetes 2016 Jul. p. 1802-P. ([Diabetes](#); vol. 64).
- * 12. Gastaldelli A, Gaggini M, Daniele G, Ciociaro D, Cersosimo, E, Tripathy D, Triplitt CL, Fox P, Musi N, Iozzo P, DeFronzo RA. Exenatide improves hepatic insulin resistance 2016 Jul. p. 1817-P. ([Diabetes](#); vol. 64).
- * 13. Al Jobori H, Daniele G, Martinez M, Adams J, Triplitt CL, DeFronzo RA, Cersosimo E. Acute glucosuric response and impact on glycemic indices of empagliflozin in nondiabetic and diabetic subjects 2016 Jul. p. 1875-P. ([Diabetes](#)).
- * 14. Iozzo P, Giuseppe D, Molina-Wilkins M, Ciociaro D, Lancaster J, Triplitt C, Cersosimo E, Fox P, Musi N, Tripathy D, DeFronzo R, Gastaldelli A. A Better Antilipolytic Effect of Insulin and Reduced Adipose Tissue Glucose Uptake after Exenatide Injection during PET-OGTT 2015 Jul. p. 2051-P. ([Diabetes](#); vol. 64).
- * 15. Cersosimo C, Xiaojing Xu, Triplitt CL, Musi N. Effect of metformin on metabolic and inflammatory insulin signaling pathways in vascular muscle cells 2014 Jul. p. 1689-P. ([Diabetes](#); vol. 64).
- * 16. Daniele, Wilkins M, Lancaster J, Ciociaro D, Triplitt CL, Cersosimo C, Tripathy D, Fox P, Musi N, Iozzo P, DeFronzo R, Gastaldelli A. Exenatide Affects the

Distribution of Cerebral Postprandial Glucose Uptake: A Double-Blind, Randomized Clinical Trial 2014 Jul. p. A85. ([Diabetes](#); vol. 63).

- * 17. Cersosimo C, Triplitt CL, Solis-Herrera C, Adams J, Garduno J, DeFronzo RA. Different hepatic effect of metformin and sitagliptin contribute to glucose lowering in type 2 diabetes 2013 Jul. p. 1883-P. ([Diabetes](#); vol. 62).
- * 18. Abdul-Ghani M, Puckett C, Adams J, Cersosimo, C, Triplitt CL, DeFronzo RA. Initial Triple Combination Therapy Is Superior to Stepwise Add-On Conventional Therapy in Newly Diagnosed T2DM 2013 Jul. p. A18. ([Diabetes](#); vol.63).

Book Chapter

- * 1. Solis-Herrera C, Triplitt C, Cersosimo E, DeFronzo RA. Pathogenesis of Type 2 Diabetes Mellitus. Endotext. South Dartmouth, Massachusetts: MDText.com, 2021
- * 2. Triplitt CL, Repas T, Alvarez C. Diabetes Mellitus. Pharmacotherapy: A Pathophysiologic Approach. 10th Edition In: Triplitt CL, Repas T, Alvarez C. Pharmacotherapy: A Pathophysiologic Approach. New York: McGraw-Hill; 2017.
- * 3. Cersosimo E, Triplitt CL, Solis-Herrera C, Mandarino LJ, DeFronzo RA. Pathogenesis of Type 2 Diabetes Mellitus In: Cersosimo E, Triplitt C, Solis-Herrera C, Mandarino LJ, DeFronzo RA. Endotext. South Dartmouth, Massachusetts: MDText.com; 2017.
- * 4. Solis-Herrera C, Triplitt C, Reasner C, DeFronzo RA, Cersosimo E. Classification of Diabetes Mellitus In: Solis-Herrera C, Triplitt C, Reasner C, DeFronzo RA, Cersosimo E. Endotext. South Dartmouth, Massachusetts:MDText.com; 2017.
- * 5. Cersosimo E, Triplitt CL, Mandarino LJ, DeFronzo RA. Pathogenesis of Type 2 Diabetes Mellitus In: Cersosimo E, Triplitt C, Mandarino LJ, DeFronzo RA. Endotext. South Dartmouth, Massachusetts: MDText.com; 2015.
- * 6. Triplitt CL, Repas T, Alvarez C. Diabetes Mellitus. Pharmacotherapy: A Pathophysiologic Approach. 9th Edition In: Triplitt CL,. Pharmacotherapy: A Pathophysiologic Approach. New York: McGraw-Hill; 2014.
- * 7. Triplitt CL, Reasner, CA. Diabetes Mellitus, Pharmacotherapy: A Pathophysiologic Approach, 8th Edition In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG and Posey LM. Diabetes Mellitus. New York, NY: McGraw-Hill Publishing, Inc.; 2011.
- * 8. Triplitt CL, Reasner CA, Isley W. Diabetes Mellitus, Pharmacotherapy: A Pathophysiologic Approach, 7th Edition In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: A Pathophysiologic Approach, 7th Edition. New York, NY: McGraw-Hill Publishing, Inc; 2008.
- * 9. Alvarez CA, Triplitt CL. Inhaled insulin therapy for patients with diabetes mellitus In: Williams, Taft, McConville. Advanced Drug Formulation Design to Optimize Therapeutic Outcomes. New York, NY: Informa Healthcare, Inc.; 2008.
- * 10. Triplitt CL, Reasner CA, Isley W. Diabetes Mellitus, Pharmacotherapy, A Pathophysiologic Approach, 6th Edition In: DiPiro, Talbert, Yee, Matzke, Wells, Posey. Pharmacotherapy: A Pathophysiologic Approach, 6th Edition. New York: McGraw-Hill; 2004.

Book/Monograph

- * 1. Triplitt CL, Alvarez CA. American Diabetes Association: Annual Review of

Diabetes 2009 Alexandria, Virginia: American Diabetes Association; 2009. 12 p.

Editorial

1. Khunti K, Triplitt CL. Improving outcomes of people with diabetes through overcoming therapeutic inertia Diabetes Spectrum 2020;33(1):5-6.
2. Triplitt CL. Oh, what times we live in! Diabetes Spectrum 2019;32(1):3-4.

Journal Article

Samms RJ, Cheng, CC, Fourcaudot M, Heikkinen S, Khattab A, Adams J, Cersosimo E, Triplitt C, Puckett C, Tsintzas K, Adams AC, Abdul-Ghani M, DeFronzo RA, Norton L. FGF21 contributes to metabolic improvements elicited by exenatide and pioglitazone in patients with type 2 diabetes. Am J Physio: Endo Metab 2022. Online

Abdul-Ghani T, Puckett C, Migahid O, Abdelgani S, Migahid A, Adams J, Triplitt C, DeFronzo, Jayyousi A, Abdul-Ghani M. Type 2 diabetes subgroups and response to glucose-lowering therapy: results from the EDICT and Qatar studies. Diabetes Obes Metab 2022. Online

- * Alatrach M, Agyin C, Solis-Herrera C, Lavryneko O, Adams J, Gastaldelli A, Triplitt C, DeFronzo RA, Cersosimo E. Dapagliflozin impairs the suppression of endogenous glucose production in type 2 diabetes following oral glucose. Diabetes Care 2022; 45:1372-1380
- * Lavryneko O, Abdul-Ghani M, Alatrach M, Puckett C, Adams J, Abdelgani S, Alkhouri N, Triplitt C, Clarke GD, Vasques JA, Jinqi L, Cersosimo E, Gastaldelli A, DeFronzo RA. Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: the efficacy and durability of initial combination therapy for type 2 diabetes (EDICT) Diabetes Obes Metab 2022;24:899-907
- * Solis-Herrera C, Qin Y, Hoka H, Clarke G, Triplitt C, Cersosimo E, DeFronzo R. Effect of elevated plasma ketones on cardiac efficiency. Am Heart J 2021;242:163
- * 1. Abdelgani S, Puckett C, Adams J, Triplitt C, DeFronzo RA, Abdul-Ghani M. Insulin secretion predicts the response to antidiabetic therapy in patients with new-onset diabetes. J Clin Endocrinol Metab 2021; 106:3497-3504
- * 2. Abdelgani S, Puckett C, Adams J, Triplitt C, DeFronzo RA, Abdul-Ghani M. Insulin secretion is a strong predictor for need of insulin therapy in patients with new-onset diabetes and HbA1C of more than 10%: a post hoc analysis of the EDICT study. Diabetes Obes Metab 2021;23:1631-1639
- * 3. Solis-Herrera C, Cersosimo E, Triplitt C. Antihyperglycemic algorithms for type 2 diabetes: focus on nonglycemic outcomes. Diabetes Spect 2021;27:2022-2039
- * 4. Kane M, Triplitt C, Solis-Herrera C. Management of type 2 diabetes with oral semaglutide: practical guidance for pharmacists Am J Health Sys Pharm 2021 Mar;78(7):556-567.

- * 5. Abdul-Ghani M, Puckett C, Adams J, Khattab A, Baskoy G, Cersosimo E, Triplitt CL, DeFronzo RA. Durability of triple therapy versus stepwise addition therapy in patients with new-onset T2DM: 3-year follow-up of EDICT Diabetes Care 2021;44(2):433-439.
- * 6. Honka, H, Solis-Herrera C, Triplitt CL, Norton L, Butler J, DeFronzo RA. Therapeutic manipulation of myocardial metabolism: JACC state-of-the-art review. Journal of the American College of Cardiology 2021;77(16):2022-2039.
- * 7. Solis-Herrera C, Daniele G, Alatrach M, Agyin C, Triplitt C, Adams J, Patel R, Gastaldelli A, Hona H, Chen X, Abdul-Ghani M, Cersosimo E, Del Prato S, DeFronzo R. Increase in endogenous glucose production with SGLT2 inhibition is unchanged by renal denervation and correlates strongly with the increase in urinary glucose excretion Diabetes Care 2020 May;43(5):1065-1069.
- * 8. Alatrach M, Laichuthai N, Martinez R, Agyin C, Ali AM, Al-Jobori H, Lavynenko O, Adams J, Triplitt C, DeFronzo R, Cersosimo E, Abdul-Ghani M. Evidence against an important role of plasma Insulin and glucagon concentrations in the increase in EGP caused by SGLT2 inhibitors Diabetes 2020;69(4):681-688.
- * 9. Ali AM, Martinez R, Al-Jobori H, Adams J, Triplitt C, DeFronzo R, Cersosimo E, Abdul-Ghani M. Combination therapy with canagliflozin plus liraglutide exerts additive effect on weight loss, but not on HbA1c in patients with type 2 diabetes. Diabetes Care 2020;43(6):1234-1241.
- * 10. Alatrach M, Lauchuthai N, Martinez R, Agyin C, Ali AM, Al-Jobori H, Lavynenko O, Adams J, Triplitt C, DeFronzo R, Cersosimo E, Abdul-Ghani M. Evidence against an important role of plasma insulin and glucagon concentrations in the increase in EGP caused by SGLT2 inhibitors Diabetes 2020;69(4):681-688.
- * 11. Patel D, Triplitt CL, Trujillo J. Appropriate titration of basal insulin in type 2 diabetes and potential role of the pharmacist Adv Ther 2019;36(5):1031-1051.
- * 12. Al Jobori H, Daniele G, Adams J, Cersosimo E, Solis-Herrera C, Triplitt C, DeFronzo RA, Abdul-Ghani M. Empagliflozin treatment is associated with improved beta cell function in T2DM J Clin Endocrinol Metab 2018;103:1402-1407.
- * 13. Martinez R, Al-Jobori H, Ali AM, Adams J, Abdul-Ghani M, Triplitt C, DeFronzo R, Cersosimo E.. Endogenous glucose production and hormonal changes in

response to canagliflozin and liraglutide combination therapy Diabetes 2018 Jan;67:1182-1189.

- * 14. Alatrach M, Agyin C, Adams J, Chilton R, Triplitt C, DeFronzo R, Cersosimo E.. Glucose lowering and vascular protective effects of cycloset added to GLP-1 receptor agonists in patients with type 2 diabetes Endocrinol Diabetes & Metab 2018;1(4):e00034
- * 15. Al Jobori H, Daniele G, Adams J, Cersosimo E, Triplitt C, DeFronzo RA, Abdul-Ghani M.. Determinants of the increase in fasting plasma ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients Diab Obes Metab 2017 Jan;19:809-813.
- * 16. Abdul-Ghani M, Migahid O, Megahed A, Adams J, Triplitt C, DeFronzo RA, Zirie M, Jayyousi A.. Combination therapy with exenatide plus pioglitazone versus basal/bolus insulin in patients with poorly controlled type 2 diabetes on sulfonylurea plus metformin Diabetes Care 2017 Jan;40:325-331.
- * 17. Al Jobori H, Daniele G, Cersosimo E, Triplitt C, Norton L, DeFronzo RA, Abdul-Ghani A.. Empagliflozin and kinetics of renal glucose transport in healthy individuals and individuals with type 2 diabetes Diabetes 2017;66:1999-2006.
- * 18. Abdul-Ghani M, Al Jobori H, Daniele G, Adams J, Cersosimo E, Triplitt C, DeFronzo R.A.. Inhibition of renal sodium-glucose cotransport with empagliflozin lowers fasting plasma glucose and improves beta cell function in subjects with impaired fasting glucose Diabetes 2017;66:2495-2502.
- * 19. Triplitt CL, Hinnen D, Valentine V. How similar are biosimilars? What do clinicians need to know about biosimilar and follow-on insulins? Clinical Diabetes 2017;35:209-216.
- * 20. Gastaldelli A, Gaggini M, Daniele G, Cersosimo E, Tripathy D, Triplitt C, Fox P, Musi, N, DeFronzo R, Izzo P. Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study. Hepatology 2016 Dec;64(6):2028-2037.
- * 21. Triplitt CL, Solis-Herrera C. GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice Diabetes Educ 2015 Dec;41(1):32S-46S.
- * 22. Daniele G, Izzo P, Molina-Carrion M, Lancaster J, Ciociaro D, Cersosimo E, Tripathy D, Triplitt C, Fox P, Musi, N, DeFronzo, R, Gastaldelli A. Exenatide Regulates Cerebral Glucose Metabolism in Brain Areas Associated With Glucose

Homeostasis and Reward System Diabetes 2015 Oct;64(10):3406-3412.

- * 23. Abdul-Ghani MA, Puckett C, Triplitt C, Maggs D, Adams J, Cersosimo E, DeFronzo RA. Initial combination therapy with metformin/pioglitazone/exenatide is more effective than sequential add-on therapy in subjects with new onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT) Diabetes Obesity Metabolism 2015 Jan;17:268-275.
- * 24. Triplitt C, Solis-Herrera C, Cersosimo E, Abdul-Ghani M, DeFronzo RA. Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus Expert Opin Pharmacother 2015;16:2819-2833.
- * 25. Triplitt CL, Cornell S. Canagliflozin treatment in patients with type 2 diabetes mellitus Clinical Medicine Insights: Endocrinology and Diabetes 2015;8:73-81.
- * 26. Cersosimo E, Xu X, Upala S, Triplitt C, Musi N.. Acute insulin resistance stimulates and insulin sensitization attenuates vascular smooth muscle cell migration and proliferation Physiol Rep 2014 Aug;2(8):1-10.
- * 27. Cersosimo E, Solis-Herrera C, Triplitt C. Inhibition of renal glucose reabsorption as a novel treatment for diabetes patients J Bras Nefrol 2014 Mar;36(1):80-92.
- * 28. Solis-Herrera C, Triplitt C, Garduno-Garcia JD, Adams J, DeFronzo RA, Cersosimo C. Mechanisms of glucose lowering of DPP-4 inhibitor sitagliptin when used alone or with metformin in type 2 diabetes: A double tracer study Diabetes Care 2013 Jan;36:2756-2762.
- * 29. Cersosimo E, Gastaldelli A, Cervera A, Wajcberg E, Sriwijilkamol A, Fernandez M, Zuo P, Petz R, Triplitt C, Musi N, Defronzo RA. Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects J Clin Endocrinol Metab 2011 Jun;96(6):1763-1770.
- * 30. Fernandez M, Gastaldelli A, Triplitt C, Hardies J, Casolaro A, Petz R, Tantiwong P, Musi N, Cersosimo E, Ferrannini E, Defronzo R. Metabolic Effects of Muraglitazar in Type 2 Diabetic Subjects Diabetes Obes Metab 2011 May;13:893-902.
- * 31. Joya-Galeana J, Fernandez M, Cervera A, Reyna S, Ghosh S, Triplitt C, Musi N, Defronzo RA, Cersosimo E. Effects of insulin and oral anti-diabetic agents on glucose metabolism, vascular dysfunction and skeletal muscle inflammation in type 2 diabetic subjects Diabetes Metab Res Rev 2011 May;27(4):373-382.
- * 32. Triplitt C, Cersosimo E, DeFronzo RA. Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment. Vasc Health Risk Manag 2010 Sep;6:671-690.
- * 33. DeFronzo RA, Triplitt C, Qu Y, Lewis MS, Maggs D, Glass LC. Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin Diabetes Care 2010 May;33(5):951-957.
- * 34. Triplitt CL, Reichert SL. Direct renin inhibition: new therapy for hypertension and maybe beyond Practical Diabetology 2009 Mar:6-15.
- * 35. Shane-McWorter L, Armor B, Johnson JT, Letassy N, Reichert S, Sisson E, Sommers-Hanson J, Triplitt C, Vivian EM. Pharmacist scope of practice,

standards of practice, and standards of professional performance for diabetes educators The Diabetes Educator 2009;35:69S-84S.

- * 36. Fernandez M, Triplitt C, Wajcberg E, Sriwijilkamol A, Musi N, Cusi K, DeFronzo RA, Cersosimo E.. Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanisms_ Diabetes Care 2008;31(1):121-127.
- * 37. Chavez AO, Lopez-Alvarengo JC, Tejero ME, Triplitt C, Bastarrachea RA, Sriwijitkamol A, Tantiwong P, Voruganti VS, Musi N, Comuzzie AG, DeFronzo RA, Folli F. Physiological and molecular determinants of insulin action in the baboon_ Diabetes 2008;57(4):899-908.
- * 38. Cervera A, Wajcberg E, Sriwijitkamol A, Fernandez M, Zuo P, Triplitt C, Musi N, DeFronzo RA, Cesosimo E. Mechanism of action of exentide to reduce postprandial hyperglycemia in type 2 diabetes American Journal of Physiology- Endocrinology and Metabolism 2008;294(5):E846-E852.
- * 39. Miyazaki Y, Cersosimo E, Triplitt C, DeFronzo RA. Rosiglitazone decreases albuminuria in type 2 diabetic patients Kidney International 2007;72(11):1367-1373.
- 40. Blonde L, Rosenstock J, Triplitt C. What are incretins, and how will they influence the management of type 2 diabetes? J Manag Care Pharm 2006 Sep;12(7 Sup):2-12.
- * 41. Triplitt C, DeFronzo RA.. Exenatide: first in class incretin mimetic for the treatment of type 2 diabetes mellitus Expert Rev Endocrinol Metab 2006 May;1(3):329-341.
- * 42. Triplitt CL, Wright A, Chiquette E. Incretin Mimetics and Dipeptidyl Peptidase IV Inhibitors: Potential New Therapies for Type 2 Diabetes Mellitus Pharmacotherapy 2006 Jan;26(3):360-374.
- * 43. Triplitt CL, Glass L, Miyazaki Y, Wajcberg E, Gastaldelli A, De Filippus E, Cersosimo E, DeFronzo RA. Comparison of Glargine Insulin Versus Rosiglitazone Addition in Poorly Controlled Type 2 Diabetic Patients on Metformin Plus Sulfonylurea Diabetes Care 2006;29:2371-2377.
- * 44. Miyazaki M, De Filippis E, Bajaj M, Wajcberg E, Glass L, Triplitt C, Cersosimo E, Mandarino LJ, DeFronzo RA.. Predictors of improved glycaemic control with rosiglitazone therapy in type 2 diabetic patients: a practical approach for the primary care physician Br J Diabetes Vasc Dis 2005 Jan;5:28-35.
- * 45. Wajcberg E, Miyazaki Y Ph.D., Triplitt C, Cersosimo E, DeFronzo RA.. Dose response effect of a single administration of oral hexyl-insulin monoconjugate 2 (HIM2) in healthy nondiabetic subjects. Diabetes Care 2004 Dec;27(12):2868-2873.
- * 46. Miyazaki Y, Glass L, Triplitt CL, Matsuda M, Cusi K, Mahankali A, Mahankali S, Mandarino LJ, DeFronzo RA. Effect of Rosiglitazone on Glucose and Non-Esterified Fatty Acid Metabolism in Type II Diabetic Patients Diabetologia 2001 Dec;44(12):2210-2219.

Review Article

- * 1. DeFronzo RA, Triplitt C, Abdul-Ghani M, Cersosimo C. Novel Agents for the Treatment of Type 2 Diabetes Diabetes Spectrum 2015 May;27(2):100-112.
- * 2. Eugenio Cersosimo, Carolina Solis-Herrera, Michael E. Trautmann, Jaret Malloy, Curtis L. Triplitt. Assessment of Pancreatic Beta-Cell Function: Review of Methods and Clinical Applications Current Diabetes Review 2014 Dec;10(1):2-42.
- * 3. Solis-Herrera C, Triplett CL, Lynch JL. Nephropathy in youth and young adults with type 2 diabetes Current Diabetes Reports 2014 Feb;14(2):456
- * 4. Triplitt CL. Understanding the kidneys' role in blood glucose regulation. Am J Manag Care 2012;18:11-16.
- * 5. Triplitt CL. Examining the mechanisms of glucose regulation Am J of Manag Care 2012;18:S4-S10.
- * 6. Triplitt CL. Managing diabetes in patients with diabetes of long duration Diabetes Educ 2012;38:23S-30S.
- * 7. Triplitt C. Cardiac risk factors and hypoglycemia in an elderly patient: how good is good enough? Consult Pharm 2010 Jun;25:19-27.
- * 8. Triplitt C. Improving treatment success rates for type 2 diabetes: recommendations for a changing environment. Am J Manag Care 2010;16:195-200.
- 9. Triplitt CL, Alvarez CA. Best practices for lowering the risk of cardiovascular disease in diabetes Diabetes Spectrum 2008;21(3):177-189.
- * 10. Triplitt C, McGill JB, Porte D, Conner CS. The changing landscape of type 2 diabetes: the role of incretin-based therapies in managed care outcomes. J Manag Care Pharm 2007 Dec;13:2-16.
- * 11. Triplitt CL. New technologies and therapies in the management of diabetes. Am J Manag Care 2007 Apr;13:47-54.
- 12. Jani R, Triplitt C, Reasner CA, DeFronzo RA. First approved inhaled insulin therapy for diabetes mellitus Expert Opin Drug Deliv 2007;4(1):63-76.
- 13. Triplitt CL. How to Initiate, Titrate, and Intensify Insulin Treatment in Type 2 Diabetes. US Pharmacist 2007;32(10):10-16.
- * 14. Triplitt CL, Chiquette E. Exenatide: From the Gila Monster to the Pharmacy J Am Pharm Assoc 2006;46:44-55.
- * 15. Triplitt CL. Drug Interactions of Medications Commonly Used in Diabetes Diabetes Spectr 2006;19:202-211.

PRESENTATIONS:

- 01/2022. Under Pressure: HTN and Diabetes, CardioRenal Connections.
University of Texas Health at San Antonio, San Antonio, TX (Invited Speaker)
Details: 3 day virtual seminar on cardiovascular, renal, metabolism, and diabetes topics.
Topic: GLP-1RA's or CV Protection
- 03/2021 Overcoming Barriers to Adherence, American Diabetes Association 68th Annual Postgraduate Course, American Diabetes Association, San Antonio, TX (Invited Speaker)
Details: 1 hour lecture within the larger 3 day conference. with live questions and answers section for participants
- 03/2021 HTN and Dyslipidemia in Diabetes, Texas Diabetes Institute- Diabetes Educators, San Antonio, TX (Sole Presenter)
Details: Continuing series of talks to TDI Diabetes educators about latest information and guidelines on HTN and Dyslipidemia in treatment of Diabetes
- 03/2021 CGM and Diabetes, Iowa Pharmacist Association- EXPO, San Antonio, TX (Co-Presenter)
Details: (Virtual). but presented to IPA pharmacist program throughout Iowa Topic: CGM and Diabetes
- 02/2021 Cardiovascular disease and Diabetes, Texas Diabetes Institute- Diabetes Educators, San Antonio, TX (Sole Presenter)
Details: Inservice to TDI Educators for CVD, CHF, HTN
- 01/2021 GLP-1 RA's and Cardiorenal Outcomes in Type 2 DM, CardioRenal Connections, University of Texas Health at San Antonio, San Antonio, TX (Invited Speaker)
Details: 3 day virtual seminar on cardiovascular, renal, metabolism, and diabetes topics.
Topic: GLP-1RA's or CV Protection
- 11/2020 Under Pressure in Diabetes: Treatment of HTN in 2020, Grand Rounds- Division of Endocrinology, Endocrinology, UTHSA, San Antonio, TX (Sole Presenter)
Details: Grand Rounds given via Zoom
- 09/2020 Clinical Pearls: ADA Standards of Care- Focus on Pharmacological Therapy, Texas Society of Health-System Pharmacists Annual Meeting, TSHP, San Antonio, TX (Invited Speaker)
Details: virtual offering due to COVID
- 08/2019 Introduction to Diabetes and Diabetes Education, Gouverneur Hospital Education Event, Manhattan NY, American Association of Diabetes Educators, New York, NY (Co-Presenter)
Details: 1 day seminar presented with RN CDE to increase knowledge to a number of professions in the Gouverneur Hospital in Manhattan, underwritten by New York Health Department
- 07/2019 Introduction to Diabetes and Diabetes Education, Gouverneur Hospital Education Event, Manhattan NY, American Association of Diabetes Educators, New York, NY (Co-Presenter)

Details: 1 day seminar presented with RN CDE to increase knowledge to a number of professions in the Gouverneur Hospital in Manhattan, underwritten by New York Health Department

- 03/2019 Core Concepts Course- 2019, American Association of Diabetes Educators Conference, AADE, Chicago, IL (Co-Presenter)
Details: Presented 3 times over 2019 Facilitator and Speaker for course to help newer diabetes educators prepare to become a Certified Diabetes Educator (CDE)
- 04/2018 Treatment of Type 2 Diabetes Mellitus, Knapp Medical Center Annual Conference, Knapp Medical Center, Weslaco, TX (Invited Speaker)
- 03/2018 Core Concepts Course- 2018, American Association of Diabetes Educators Conference, AADE, Chicago, IL (Co-Presenter)
Details: Revamped program where 1 day is home study and 2 days in person with faculty. Facilitator and Speaker for course to help newer diabetes educators prepare to become a Certified Diabetes Educator (CDE)
- 12/2017 Individualizing Type 2 DM Treatments with GLP-1 RA CVOT Data, American Association of Diabetes Educators Webinar, AADE, San Antonio, TX (Sole Presenter)
- 11/2017 Explaining Cardiovascular Disease and Diabetes, American Association of Diabetes Educators Webinar, AADE, San Antonio, TX (Sole Presenter)
- 08/2017 Core Concepts Course, American Association of Diabetes Educators Conference, AADE, Indianapolis, IN (Co-Presenter)
Details: Facilitator and Speaker for 3 day course to help newer diabetes educators prepare to become a Certified Diabetes Educator (CDE)
- 06/2017 Patient-Centered Strategies to Minimize Cardiovascular Risk in Patients, Academy of Managed Care Pharmacy Webinar, AMCP, San Antonio, TX (Co-Presenter)
Details: Presented 4 times as a webinar (live) over 2017
- 05/2017 Treatment of Diabetes Mellitus, Morning Grand Rounds, Physical Medicine & Rehabilitation Residents, Audie L Murphy Veteran's Administration Hospital, San Antonio, TX (Invited Speaker)
Details: Invited speaker on Initiation and Titration of Insulin therapy for patients. Extensive questions on insulin placement, action, clinical scenarios by medical students, residents, and attendings
- 04/2017 Core Concepts Course, American Association of Diabetes Educators Conference, AADE, Tampa, FL (Co-Presenter)
Details: Facilitator and Speaker for 3 day course to help newer diabetes educators prepare to become a Certified Diabetes Educator (CDE)
- 03/2017 Core Concepts Course, American Association of Diabetes Educators Conference, AADE, Las Vegas, NV (Co-Presenter)
Details: Facilitator and Speaker for 3 day course to help newer diabetes educators prepare to become a Certified Diabetes Educator (CDE)

- 03/2017 Patient-Centered Strategies to Minimize Cardiovascular Risk in Patients in a Managed Care Setting, Academy of Managed Care and Specialty Pharmacy Meeting, AMCP, Denver, CO (Invited Speaker)
- 02/2017 Clinical Pearls for Type 2 Diabetes, Iowa Pharmacy Expo, Iowa Pharmacists Association, Des Moines, IA (Invited Speaker)
- 12/2016 What's New in Diabetes Mellitus Treatment, Texas Podiatric Medical Association Annual Meeting, Texas Podiatric Medical Association, San Antonio, TX (Invited Speaker)
- 12/2016 What You Need to Know: Individualization of Insulin Therapy in Type 2 DM, American Society of Health System Pharmacists Annual Meeting, ASHP, Las Vegas, NV (Invited Speaker)
- 10/2016 Core Concepts Course, American Association of Diabetes Educators Conference, AADE, Richmond, VA (Co-Presenter)
Details: *Facilitator and Speaker for 3 day course to help newer diabetes educators prepare to become a Certified Diabetes Educator (CDE)*
- 10/2016 Hypertension Management in Diabetes, Grand Rounds, Endocrinology, UTHSCSA, San Antonio, TX (Sole Presenter)
- 09/2016 Core Concepts Course, American Association of Diabetes Educators Conference, AADE, Dallas, TX (Co-Presenter)
Details: *Facilitator and Speaker for 3 day course to help newer diabetes educators prepare to become a Certified Diabetes Educator (CDE)*
- 07/2016 Diabetes Education Principles, Georgia Public Health Annual Meeting, American Association of Diabetes Educators, Atlanta, GA (Co-Presenter)
Details: *1 day seminar to HCP's to improve their understanding of diabetes education*
- 07/2016 Diabetes Education Principles, Georgia Public Health Satellite Meeting, American Association of Diabetes Educators, Savannah, GA (Co-Presenter)
Details: *1 day seminar to HCP's to improve their understanding of diabetes education*
- 05/2016 A Box of Crayons: Treatment of Type 2 DM in 2016, Central Texas Society of Health System Pharmacists Annual Meeting, Central TSHP, San Antonio, TX (Invited Speaker)
- 04/2016 A Box of Crayons: Treatment of Type 2 DM in 2016, Texas Excels in Diabetes Education and Care, 4th Annual Conference, Texas State AADE Conference, Austin, TX (Invited Speaker)
- 03/2016 Core Concepts Course, American Association of Diabetes Educators Conference, AADE, Las Vegas, NV (Co-Presenter)
Details: *Facilitator and Speaker for 3 day course to help newer diabetes educators prepare to become a Certified Diabetes Educator (CDE)*
- 10/2015 Core Concepts Course, American Association of Diabetes Educators Conference, AADE, Chicago, IL (Co-Presenter)

Details: *Facilitator and Speaker for 3 day course to help newer diabetes educators prepare to become a Certified Diabetes Educator (CDE)*

- 10/2015 Maximizing the Role of GLP-1 Agonists in Our Patients with Type 2 Diabetes, New Mexico Society of Health-System Pharmacists Annual Meeting, New Mexico Society of Health-System Pharmacists, Albuquerque, NM (Invited Speaker)
- 10/2015 Type 2 Diabetes: Mechanisms of Disease and Drugs, Pharmacy Practice and Administrative Science Lecture Series, College of Pharmacy, University of New Mexico, Albuquerque, NM (Invited Speaker)
Details: *University of New Mexico College of Pharmacy, Noon Conference to students, residents, and faculty of UNM COP about type 2 DM and DM Research Techniques*
- 09/2015 New and Emerging Treatment Options for Type 2 DM, Carle Hospital System Regional Diabetes Symposium, Carle Hospital System, Champaign, IL (Invited Speaker)
- 09/2015 Maximizing the Role of GLP-1 Agonists in Our Patients with Type 2 Diabetes, Illinois Chapter of Health-System Pharmacists Annual Meeting, Illinois Chapter of Health-System Pharmacists, Oakbrook Terrace, IL (Invited Speaker)
- 08/2015 New and Emerging treatment Options for Diabetes, American Association of Diabetes Educators Annual Conference, AADE, New Orleans, LA (Co-Presenter)
- 08/2015 New Medications for the Treatment of Diabetes, Military Families Learning Network, Nutrition and Wellness, Military Families Learning Network, Coordinated by University of Illinois-Urbana, Urbana, IL (Invited Speaker)
Details: *Practical information to military families struggling with many issues with diabetes mellitus*
- 06/2015 Treating Common Chronic Disease in the Elderly: The Multiplicity of Multimorbidity, Texas Clinical Nurse Specialist Conference, Texas Clinical Nurse Specialists, Austin, TX (Invited Speaker)
Details: *2 hours of lecture: 1 hour on HTN treatment, 1 hour on Dyslipidemia*
- 05/2015 Maximizing the Role of GLP-1 Agonists in Our Patients with Type 2 Diabetes, American Society of Health System Pharmacists Webinar, ASHP, San Antonio, TX (Co-Presenter)
Details: *Given again 06/2015 as an encore performance*
- 05/2015 Case Studies in the Use of GLP-1 Agonists in Type 2 Diabetes Management: An Individualized Approach to Patient Care, American Society of Health System Pharmacists Webinar, ASHP, San Antonio, TX (Invited Speaker)
Details: *Presented twice in 2015 to national pharmacist audience*

- 12/2014 Prevention and Treatment of Diabetic Eye Disease, American Society of Health System Pharmacists Annual Meeting, ASHP, Anaheim, CA (Invited Speaker)
- 12/2014 Novel Treatments for the Management of Type 2 DM: Focus on SGLT2 inhibitors, American Society of Health System Pharmacists Annual Meeting, ASHP, Anaheim, CA (Co-Presenter)
- 10/2014 Core Concepts Course, American Association of Diabetes Educators Conference, AADE, Phoenix, AZ (Co-Presenter)
Details: *Facilitator and Speaker for 3 day course to help newer diabetes educators prepare to become a Certified Diabetes Educator (CDE)*
- 04/2014 The Cog Has Shifted Again: The Evolution of Diabetes Standards and Treatments, Texas Society of Health-System Pharmacists Annual Meeting, TSHP, Houston, TX (Invited Speaker)
- 02/2014 Core Concepts Course, American Association of Diabetes Educators Conference, AADE, Las Vegas, NV (Co-Presenter)
Details: *Facilitator and Speaker for 3 day course to help newer diabetes educators prepare to become a Certified Diabetes Educator (CDE)*
- 02/2014 Ask the Experts: A Controversial Dialogue in Diabetes, Nationwide Webinar, American Society of Health-System Pharmacists, San Antonio, TX (Co-Presenter)
Details: *Delivered 2 times over 2013-2014 as National Webinar for ASHP*
- 12/2013 Managing Hyperglycemia in Inpatients: Ensuring Success, American Society of Health System Pharmacists, ASHP, Orlando, FL (Co-Presenter)
Details: *Chairman of Activity*
- 11/2013 Treatment of Hypertension in Diabetes Mellitus, Post-Graduate Training, Medicine/Diabetes, UTHSCSA, San Antonio, TX (Invited Speaker)
Details: *Lecture to Post-Graduate Trainees in Division of Diabetes*
- 10/2013 Patient-Centered Diabetes Care, Academy of Managed Care Pharmacy, NEXUS Meeting, Academy of Managed Care Pharmacy, San Antonio, TX (Invited Speaker)
- 07/2013 Safe and Effective Use of Insulin in the Inpatient Setting, Georgia Society of Health-System Pharmacists Annual Meeting, Georgia Society of Health-System Pharmacists, Amelia Island, FL (Invited Speaker)
Details: *Inpatient insulin use tutorial for inpatient pharmacists*
- 03/2013 Vaccinations and Victories: Treatment of Type 2 Diabetes Mellitus, American Diabetes Association, Wisconsin Affiliate Annual Meeting, Wisconsin Affiliate, American Diabetes

Association, Appleton, WI (Invited Speaker)

- 11/2012 Treatment of Hypertension in Diabetes: Time for Reassessment?, Texas Teleconference Network, UTHSCSA, San Antonio, TX (Invited Speaker)
Details: *Nationwide teleconference through UTHSCSA*
- 06/2012 Pathophysiologic Treatment of Type 2 DM and the Titanic: Lessons Learned, Midwestern University College of Pharmacy Diabetes Symposium, College of Pharmacy, Midwestern University, Oak Brook, IL (Keynote Speaker)
Details: *Keynote speaker for Annual COP Symposium*
- 03/2012 Oportunities for Pharmacists: Discussing the Role of GLP-1 Agonists as a Means to Improve Type 2 Diabetes Patient Care, Annual Conference-APhA, Satellite Symposium, American Pharmaceutical Association, New Orleans, LA (Co-Presenter)
Details: *Invited speaker for increasing knowledge in GLP-1 RA's, a newer diabetes medication*
- 03/2012 Sound Treatment of Diabetes. The Texas Diabetes Council Treatment Algorithms, Texas Association of Health Plan Medical Directors Meeting, Texas Association of Health Plan Medical Directors, Austin, TX (Invited Speaker)
Details: *Invited speaker to present TDC algorithms to Texas Managed Care Health Plans to advocate for more aggressive assessment and treatment and open formularies to help Texans with or at risk of diabetes.*
- 08/2011 Emerging Therapies and Concepts for the Treatment of Type 2 Diabetes Mellitus: Vacillations & Victories, Annual Meeting- AADE, Diabetes Educators, American Association of Diabetes Educators, Las Vegas, NV (Invited Speaker)
- 07/2011 Standards of Care: Diabetes Education for Success, Grand Rounds, Family Medicine and Community Medicine/ School of Public Health, UTHSCSA, San Antonio, TX (Invited Speaker)
- 10/2010 Hypertension and Diabetes: A Deadly Duet, TNT, Allied Health Care and Physicians, Texas Teleconference Network, UTHSCSA, San Antonio, TX (SolePresenter)
- 10/2010 Diabetes, Where We Were, Where We Are, and Where We May be Going, Conference, Health Care Executives and Administrators, South Texas Chapter, American College of Healthcare Executives, San Antonio, TX (Invited Speaker)
- 08/2010 New Diabetes Medications, New Questions, Teleconference TNT Network, Allied Health,

UTHSCSA, San Antonio, TX (Sole Presenter)

- 08/2010 The Treatment of Hypertension in Patients with Diabetes: Lowering of Pressure Through Sound Practice, Annual Meeting-AADE, RD, LD, RN, PA, RPh, MD, American Association of Diabetes Educators, San Antonio, TX (Invited Speaker)
Details: *National Meeting for diabetes educators*
- 08/2010 Latest Review of Diabetes Medications, Annual Meeting- AADE, Allied Health Care Professions, American Association of Diabetes Educators, San Antonio, TX (Invited Speaker)
- 07/2010 Hypertension and Diabetes: An Update, Southwest Seminar-Texas Diabetes Institute, Allied Health, MD, Texas Diabetes Institute, San Antonio, TX (Invited Speaker)
- 07/2010 Getting to Goal for Patients with Type 2 Diabetes, Annual Conference- Texas Pharmacists Association, Pharmacists, Texas Pharmacy Association, Austin, TX (Invited Speaker)
- 12/2009 Update on Diabetes Mellitus, Annual Meeting- ASHP, Pharmacists, American Society of Health System Pharmacists, Las Vegas, NV (Co-Presenter)
Details: *Given daily for 4 consecutive days as a CE program*
- 08/2008 Who's Treating Diabetes Patients Anyway?, Annual Meeting- AADE, RD, RN, NP, PA, RPh, MD, American Association of Diabetes Educators, Washington, DC (Co-Presenter)
Details: *Presented with allied health care team on role of pharmacist in treatment of diabetes mellitus*
- 08/2008 Advance Medication Management, Annual Meeting- AADE, RD, RN, RPh, NP, PA, MD, American Association of Diabetes Educators, Washington, DC (Invited Speaker)
Details: *Invited to give the update on advance medication management to diabetes education specialists*
- 09/2007 Type 2 Diabetes: Contribution of Gut Hormones to Glycemic Control, Young European Scientist Meeting, MD, MD students, Faculty of Medicine, University of Porto, Portugal, Porto, Portugal, Portugal (Invited Speaker)
Details: *Invited speaker and researcher <40 year of age*
- 08/2007 The Future is in Your Gut; How Gut Hormone Therapy May Change Your Practice, and Maybe Your Life., Annual Meeting- AADE, RD, RN, RPh, PA, NP, MD, American Association of Diabetes Educators, St. Louis, MO (Invited Speaker)
Details: *Talk on multiple hormones from gut including PYY, GLP-1, GIP, etc.*
- 10/2006 Glucose Control: Surgery and Illness, Southwest Seminar, Allied Health Care, MD's, Texas Diabetes Institute, San Antonio, TX (Invited Speaker)
- 04/2006 New Agents in the Treatment of Diabetes Mellitus: Peptides, Pills, and Pulmonary Delivery, Annual Conference- TSHP, Pharmacists, Texas Society of Health-System Pharmacists, Galveston, TX (Invited Speaker)
Details: *Also given to Central Texas Society of Health-System Pharmacists, 10-2006*

- 03/2006 Intensive Insulin Treatment of Type 2 Diabetes, Annual Meeting- APhA, Pharmacists, American Pharmaceutical Association, San Francisco, CA (Co-Presenter)
Details: *co-presented with Professor of Pharmacy from North Carolina*
- 08/2005 Combination Hypertension and Dyslipidemia Therapy: Why so Many Drugs?, Annual Meeting- AADE, Diabetes Educators RD, RN, RPh, PA, NP, MD, American Association of Diabetes Educators, Washington, DC (Sole Presenter)
- 04/2005 Glycemic Control and Cardiovascular Disease, Annual Meeting- TSHP, Pharmacists, Texas Society of Health-System Pharmacists, Austin, TX (Invited Speaker)
- 04/2005 Diabetes and Hypertension, Grand Rounds, Varies, UTHSCSA, San Antonio, TX (Sole Presenter)
Details: *Medicine Grand Rounds*
- 08/2004 Many Medications, Many Misfortunes? The Risk for Drug Interactions, Annual Meeting- AADE, Diabetes Educators RD, RN, RPh, PA, NP, MD, American Association of Diabetes Educators, Indianapolis, IN (Invited Speaker)
Details: *National meeting for AADE, invited speaker*
- 07/2004 Insulin Therapy and the Other Insulin Resistance Syndrome, Texas Pharmacy Association Annual Meeting, TPA, Dallas, TX (Sole Presenter)
- 04/2004 Pathophysiology, Etiology, and Treatment of Hypertension, Ophthalmology/Optometry UTHSCSA CE Program, UTHSCSA, San Antonio, TX (Sole Presenter)
- 04/2004 Core Concepts- Diabetes Review Course, Seminar Series, RD, LD, RN, RPh, American Association of Diabetes Educators, Chicago, IL (Co-Presenter)
Details: *Faculty chosen from national pool of educators. 3 day review course given by Dr. Triplitt Fall 2003, Spring, 2004, Fall 2004, Spring 2006, and once in 2010.*
- 03/2004 Insulin Therapy and the Other Insulin Resistance Syndrome, ADA South Texas Region Diabetes EXPO, ADA, San Antonio, TX (Sole Presenter)
Details: *Also given at Texas Pharmacy Association South Texas Regional Meeting 4/04 Alamo Chapter, AADE, 3/04*
- 12/2003 Treatment of Hypertension in Patients with Diabetes, Seminar Series-Diabetes, Texas Teleconference Network, UTHSCSA, San Antonio, TX (Sole Presenter)
- 11/2003 Diabetes & Aging, Annual Meeting- TPA, Texas Pharmacy Association, Texas Affiliate of American Society of Consultant Pharmacists, Austin, TX (Sole Presenter)
- 10/2003 Chronic Complication and Co-existing Conditions of Diabetes Mellitus,

- Ophthalmology/Optometry UTHSCSA CE Program, UTHSCSA, San Antonio, TX (Sole Presenter)
- 10/2003 Diabetes Review Course, Texas Diabetes Institute, RD, LD, RN, RPh, NP, PA, Texas Diabetes Institute, San Antonio, TX (Co-Presenter)
Details: *Diabetes Education Review for the Pharmacist- given over 15 times from 1998
Diabetes Disease State Management for the Case Manager- Offered twice in 1999*
- 07/2003 New HOPE for Cardiovascular Risk Reduction in Patients with Diabetes, Texas Pharmacy Association Annual Meeting, Texas Pharmacy Association, Galveston, TX (Sole Presenter)
- 06/2003 Diabetes: What You Need to Know, Seminar series, Texas Medical Association/Texas Alliance for Continuing Medical Education, San Antonio, TX (Sole Presenter)
- 01/2003 Prevention of Diabetes: The A's Have the Answer, Seminar Series, Texas Teleconference Network, UTHSCSA, San Antonio, TX (Sole Presenter)
- 08/2002 Basic Pharmacological Options in the Treatment of Type 2 Diabetes, Annual Conference- AADE, RN, RPH, CDE, LD/RD, American Association of Diabetes Educators, Philadelphia, PA (Sole Presenter)
- 01/2002 Locked and Loaded for Lipid Lowering, Seminar Series-TNT, Texas Teleconference Network, UTHSCSA, San Antonio, TX (Sole Presenter)
- 01/2001 HbA1c: How Low Should We Go?, Annual Conference- ACCP, Ambulatory Care, American College of Clinical Pharmacy, Tampa, FL (Sole Presenter)
- 01/2001 Diabetes: Confronting the Epidemic, Public Forum, UTHSCSA/ADA/Pharmaceutical Research and Manufacturers of America, San Antonio, TX (Co-Presenter)
- 01/2001 Adding to the Armamentarium for Type 2 Diabetes, Seminar Series, Texas Teleconference Network, UTHSCSA, San Antonio, TX (Sole Presenter)
Details: *Teleconference Series*
- 09/2000 Clinical Implications of the UKPDS, Annual Meeting-Oklahoma South District Pharmacists Association, Pharmacists, Oklahoma Pharmacy Association, Southern District Meeting, OK (Sole Presenter)
- 08/2000 Why Treat Dyslipidemia?, Annual Conference- TSHP, Pharmacists, Texas Society of Health-System Pharmacists, Austin, TX (Sole Presenter)
- 10/1999 Diabetes Education for the Pharmacist, Seminar, Pharmacists, University of New Mexico College of Pharmacy, Albuquerque, NM (Co-Presenter)
Details: *2 day seminar through Texas Diabetes Institute*
- 01/1999 Comprehensive Diabetes Disease State Management for the Case Manager, Seminar Series, RN, RPh, LD, Texas Diabetes Institute, San Antonio, TX (Co-Presenter)

Details: Offered twice in 1999

- 12/1998 Making Dollars and Sense Out of Reimbursement, Seminar, Pharmacists, Texas Diabetes Institute/TSHP, San Antonio, TX (Panel)
Details: Chair, Host, and Facilitator of the Program
- 04/1998 Physical Assessment of the Diabetic Patient, Annual Conference- TSHP, Pharmacists, Texas Society of Health System Pharmacists, Houston, TX (Sole Presenter)
- 04/1998 Diabetes Education and the Pharmacist: Opportunity Awaits, Annual Conference- TSHP, Pharmacists, Texas Society of Health System Pharmacists, Houston, TX (Sole Presenter)
- 01/1998 Comprehensive Diabetes Disease State Management for the Pharmacist, Seminar Series, Pharmacists, Texas Diabetes Institute, San Antonio, Beaumont, Tyler, Dallas, Austin, El Paso, TX (Co-Presenter)
Details: Presented 14 times over 2 years span. Facilitator for program and presenter on multiple topics

RESEARCH GRANTS:**Federal****Project #:** 17-582H**Funding Agency:** NIH**Title:** SGLT2 INHIBITION AND STIMULATION OF ENDOGENOUS GLUCOSE PRODUCTION Significance : Protocol- 4 Can the GLP-1 Receptor Agonist, Exenatide, Prevent the Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria**Status:** Active**Period:** 01/2017 - Present**Role:** Contributor**% Effort:****Total Costs:****Grant Detail:** Acute GLP-1RA or SGLT2i or combo followed by Chronic in same groups to see affects on multiple outcomes such as glycemic, insulin, glucagon etc**Project #:** 17-214H**Funding Agency:** NIH**Title:** Effect of Empagliflozin on hepatic glucose metabolism: role of autonomic nervous system**Status:** Active**Period:** 01/2017 - Present**Role:** Contributor**% Effort:****Total Costs:****Grant Detail:** Explore the potential ways SGLT2i may contribute to EGP increase-focus on autonomic nervous system mechanisms**Project #:** 16-042H**Funding Agency:** NIH**Title:** SGLT2 INHIBITION AND STIMULATION OF ENDOGENOUS GLUCOSE

PRODUCTION Significance - PROTOCOL 3: Role of the Renal Nerves in the Increase in EGP in Response to Glucosuria

Status: Complete

Period: 01/2016 - 01/2019

Role: Contributor

% Effort:

Total Costs:

Grant Detail: Renal transplant patients given SGLT2i to see affect on EGP.

Project #: 16-668H

Funding Agency: NIH

Title: SGLT2 Inhibition and Stimulation of Endogenous Glucose Production - PROTOCOL 2: Elucidation of Mechanisms Responsible for the Increase in EGP Following SGLT2 Inhibition: Decrease in Plasma Glucose Conc or Change in Islet Hormone (Glucagon/Insulin) Secret

Status: Complete

Period: 01/2016 - 01/2019

Role: Contributor

% Effort:

Total Costs:

Grant Detail: EGP clamps in patients given SGLT2i doses to see affect on EGP.

Project #: 13-205H

Funding Agency: NIH

Title: The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE Study)

Status: Active

Period: 01/2013 - Present

Role: Contributor

% Effort:

Total Costs:

Grant Detail: Compare best second medication after metformin. SU, Liraglutide, basal insulin, or DPP-4inhibitor

Project #: 08-0456H

Funding Agency: NIH

Title: Durability of Early Combination Therapy vs Conventional Therapy in New Onset Diabetes

Status: Active

Period: 01/2008 - Present

Role: Contributor

% Effort:

Total Costs:

Grant Detail: Comparison of combination from diagnosis of metformin/pioglitazone/GLP-1RA versus step-therapy with metformin/SU/basal insulin

Private

Project #: 20-230H

Funding Agency: Poxel

Title: A randomized, double-blind, placebo-controlled, parallel group trial to assess the efficacy and safety of PXL770 versus placebo after 12 weeks of treatment in patients with Nonalcoholic Fatty Liver Disease (NAFLD) with or without type 2 diabetes mellitus

Status: Complete

Period: 01/2020 - 01/2021

Role: Contributor

% Effort:

Total Costs:**Grant Detail:** Poxel small molecule to potentially affect fatty liver NASH.**Project #:** 18-077H**Funding Agency:** Merck**Title:** SGLT2 INHIBITORS, KETONES, & Cardiovascular Benefit**Status:** Active**Period:** 01/2018 - Present**Role:** Contributor**% Effort:****Total Costs:****Grant Detail:** Explore potential MOA of SGLT2i's on CV protection. BOHB infusions to see affect on cardiac metabolism**Project #:** 18-0515H**Funding Agency:** JDRF**Title:** Can Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration?
CTMS**Status:** Active**Period:** 01/2018 - Present**Role:** Contributor**% Effort:****Total Costs:****Grant Detail:** SGT2i to type 1 Dm patients, and exploration of adding pioglitazone if ketones become higher than normal.**Project #:** 16-0597H**Funding Agency:** AZ**Title:** Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM**Status:** Active**Period:** 01/2016 - Present**Role:** Contributor**% Effort:****Total Costs:****Grant Detail:** explore beta cell effects of GLP-1RA**Project #:** 16-596H**Funding Agency:** AZ**Title:** Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism**Status:** Active**Period:** 01/2016 - Present**Role:** Contributor**% Effort:****Total Costs:****Grant Detail:** Exploration of dapagliflozin and hepatic versus renal contribution to EGP**Project #:** 16-262H**Funding Agency:** AZ**Title:** EFFECT OF FARXIGA ON RENAL FUNCTION AND SIZE IN TYPE 2 DIABETIC

PATIENTS WITH HYPERFILTRATION**Status:** Active**Period:** 01/2016 - Present**Role:** Contributor**% Effort:****Total Costs:****Grant Detail:** Exploring effect of SGLT2i on renal dynamics as well as renal size**Project #:****Funding Agency:** ADA**Title:** Preservation of Beta Cell Function in pre-diabetes in subject with impaired fasting glucose (IFG) and impaired glucose tolerance (IGT).**Status:** Active**Period:** 07/2013 - 06/2016**Role:** Contributor**% Effort:****Total Costs:** \$920,000.00**Grant Detail:** Impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) have distinct pathophysiologic etiologies. Therefore, therapeutic interventions designed to correct the specific underlying pathogenic abnormalities in IGT and IFG will be required to optimally prevent the progressive beta cell failure and development of overt type 2 diabetes.**Project #:** 12-300H**Funding Agency:** MSDC**Title:** Evaluation of the Mechanism of Action of MSDC-0602K in Type 2 Diabetic Patients (Protocol MSDC-0602K-C007UT)**Status:** Complete**Period:** 01/2012 - 01/2015**Role:** Contributor**% Effort:****Total Costs:****Grant Detail:** Explore MSDC medication that could be new insulin sensitizer without side effects of medication such as pioglitazone**Project #:** 06-0280H**Funding Agency:** Takeda**Title:** Myocardial Dysfunction in Type 2 Diabetes Mellitus (T2DM) - Role of Intramyocellular Lipid Content and Mitochondrial Dysfunction in Myocardial Insulin Resistance and their Correction with Pioglitazone**Status:** Complete**Period:** 01/2006 - 01/2010**Role:** Contributor**% Effort:****Total Costs:****Grant Detail:** exploration of pioglitazone for intramyocellular effects and mitochondrial effects**Project #:****Funding Agency:** Sankyo**Title:** The effects of olmesartan medoxomil, losartan potassium, and atenolol on insulin sensitivity in overweight and obese subjects with hypertension.

Status: Complete

Period: 01/2006 - 01/2008

Role: Co-Investigator

% Effort: 30

Total Costs: \$145,250.00

Grant Detail: The effects of olmesartan medoxomil, losartan potassium, and atenolol on insulin sensitivity in overweight and obese subjects with hypertension as assessed by OGTT and by euglycemic hyperinsulinemic clamp.

Project #:

Funding Agency: Novartis

Title: The Role of Inflammatory, Adipocytokines, and Insulin Signaling and Sensitivity in the Prevention of Type 2 Diabetes Mellitus in Hypertensive Subjects Treated with Valsartan

Status: Active

Period: 07/2005 - Present

Role: Co-Investigator

% Effort: 10

Total Costs: \$50,000.00

Grant Detail: The Role of Inflammatory, Adipocytokines, and Insulin Signaling and Sensitivity in the Prevention of Type 2 Diabetes Mellitus in Hypertensive Subjects Treated with Valsartan

Project #:

Funding Agency: Novo Nordisk

Title: Combination Therapy of Metformin with Once Daily Evening Dose of Insulin Detemir (NN304) or Human Insulin NPH: Comparison of Safety and Efficacy in Subjects with Type 2 Diabetes Previously Inadequately Controlled with Monotherapy or Oral Combination

Status: Complete

Period: 06/2005 - 06/2006

Role: Co-Investigator

% Effort: 5

Total Costs: \$66,285.00

Grant Detail: Combination Therapy of Metformin with Once Daily Evening Dose of Insulin Detemir (NN304) or Human Insulin NPH: Comparison of Safety and Efficacy in Subjects with Type 2 Diabetes Previously Inadequately Controlled with Monotherapy or Oral Combination

Project #:

Funding Agency: Amylin Pharmaceuticals

Title: A Phase 3, Randomized, Triple-Blind, Parallel-Group, Long-Term, Placebo-Controlled, Multicenter Study to Examine the Effect of Glucose Control (HbA1c) of

AC2993 Given Two Times a Day in Subjects With Type 2 Diabetes Mellitus

Status: Complete

Period: 02/2003 - 06/2004

Role: Co-Investigator

% Effort: 20

Total Costs: \$105,841.00

Grant Detail: A Phase 3, Randomized, Triple-Blind, Parallel-Group, Long-Term, Placebo-Controlled, Multicenter Study to Examine the Effect of Glucose Control (HbA1c) of AC2993 Given Two Times a Day in Subjects With Type 2 Diabetes Mellitus

Project #: 03-0209H

Funding Agency: Takeda

Title: ACTOS NOW for Prevention of Diabetes (ACT NOW)

Status: Complete

Period: 01/2003 - 01/2016

Role: Contributor

% Effort:

Total Costs:

Grant Detail: Explore pioglitazone in the prevention of T2DM

Project #:

Funding Agency: Sanofi-Aventis

Title: Addition of Glargine Insulin Versus Rosiglitazone in Diabetic Subjects Poorly Controlled on Maximum Dose Metformin/Sulfonylurea Therapy.

Status: Complete

Period: 07/2002 - 06/2004

Role: Co-Investigator

% Effort: 30

Total Costs: \$347,292.00

Grant Detail:

Project #:

Funding Agency: Bristol Myers Squibb

Title: Mechanism of Action and Efficacy of Muraglitazar (BMS29585) in the Treatment of Type 2 Diabetes Patients

Status: Complete

Period: 07/2002 - 06/2004

Role: Co-Investigator

% Effort: 10

Total Costs: \$721,493.00

Grant Detail: Mechanisms of action of Muraglitazar in the Treatment of Type 2 Diabetes. OGTT, Euglycemic clamp, deuterated water.

Project #:

Funding Agency: Mannkind

Title: Efficacy and safety of inhaled technosphere/insulin compared to technosphere/placebo in patient with type 2 diabetes mellitus following diabetes education

Status: Complete

Period: 01/2001 - 01/2003

Role: Co-Investigator

% Effort:

Total Costs: \$55,105.00

Grant Detail: Efficacy and safety of inhaled technosphere/insulin compared to technosphere/placebo in patient with type 2 diabetes mellitus following diabetes education

Project #:**Funding Agency:** Nobex**Title:** A Single-Center Randomized, Open-Label, Crossover Clinical Trial Designed to Evaluate Dose Response, and Inter Subject Variability Following a Single Dose of Orally Administered Hexyl-Insulin M2, (HIM2), in Health Adult Subjects**Status:** Complete**Period:** 01/2001 - 01/2002**Role:** Co-Investigator**% Effort:** 20**Total Costs:** \$281,452.00**Grant Detail:** To evaluate the effect of a single oral dose of hexyl-insulin monoconjugate 2 (HIM2) on the rate of whole-body glucose disposal (Rd) and endogenous glucose production (EGP) in healthy nondiabetic subjects, 2) to examine the reproducibility of HIM2 on glucose metabolism, and 3) to compare the results obtained with HIM2 with those using a bioequivalent dose of subcutaneous lispro insulin.**Project #:****Funding Agency:** Bristol Myers Squibb**Title:** Comparison of Metformin (Glucophage) versus Troglitazone (Rezulin) on Glucose Tolerance, Insulin Secretion, Insulin sensitivity, Gluconeogenesis, Plasma Lipid Levels, and Fat Topography in Type 2 Diabetic Patients**Status:** Complete**Period:** 01/1999 - 08/2005**Role:** Co-Investigator**% Effort:** 60**Total Costs:** \$510,920.00**Grant Detail:** Comparison of Metformin (Glucophage) versus Troglitazone (Rezulin) on Glucose Tolerance, Insulin Secretion, Insulin sensitivity, Gluconeogenesis, Plasma Lipid Levels, and Fat Topography in Type 2 Diabetic Patients**SERVICE****ADMINISTRATIVE RESPONSIBILITIES:**

<u>Dates</u>	<u>Type</u>	<u>Description</u>	<u>Role</u>
01/2012-Present		Co-Director Diabetes Division Clinical Research Unit- Texas Diabetes Institute, University Health System	Co-Director

*Co-director with Medical Director of TDI CRU.**Coordinate research studies, procedures, nursing coordinators, oversee proper procedures*

followed for all research studies, ensure proper use of medications, involved with all audits, in charge of SOP's, oversee maintenance of equipment, directly help and perform research procedures, training of post-doc fellows for proper procedures of research studies and training on equipment used, involved with all personnel issues with Medical Director.

OTHER SERVICE:

<u>Dates</u>	<u>Type</u>	<u>Description</u>	<u>Role</u>
01/2019-12/2020		Xeris Pharmaceuticals	Speaker
		<i>Speaker for DM expertise-dissemination of risk of hypoglycemia in diabetes</i>	
01/2019-Present		Medisys Corporation Cleveland OH	Consultant
		<i>Recognized as DM expert. Consulted in evening meetings (via zoom) weekly with team of CEO, technology experts, and physicians who strived to build an AI smart platform to augment current EMR's. As consultant was asked detailed questions about all aspects of Type 2 DM pathophysiology, diagnosis, goals, medications, concerns from clinicians, clinical pearls, feedback on screen appearance of data, CGM incorporation and interpretation, hundreds of clinical scenarios and how I would treat patients, also concerns, dosing, contraindications, and comorbidity data. Literature backup was necessary to provide for above questions.</i>	
01/2019-Present		Eli Lilly	Speaker
		<i>Speakers Bureau for Dm expertise- Teach about proper use of insulin</i>	
01/2019-Present		Novo Nordisk	Speaker
		<i>Speakers bureau for DM expertise- GLP-1RA medications for treatment of T2DM and proper placement in therapy</i>	
01/2017-12/2018		Boehringer Ingelheim	Speaker
		<i>Speakers Bureau for DM expertise- disseminate information about CV indication for SGLT2i based diabetes medication</i>	
01/2016-01/2021		Speaker- Astra Zeneca	Speaker
		<i>Recognized as diabetes expert speaker. On Speaker's Bureau</i>	

PATIENT CARE:

<u>Dates</u>	<u>Type</u>	<u>Description</u>	<u>Role</u>
09/1997-Present	Outpatient	Clinical Diabetes Clinic- Texas Diabetes Institute, University Health System	Clinician

Clinical Practice:

1997-2015

3- 1/2 day sessions per week

Patients are scheduled for endocrinologist: Charles Reasner, MD

See independently 3-7 patients/ session, PE performed and targeted PE f/u by endo, write

note, and then check out to endocrinologist with interview, amendments and attestations by endocrinologist.

2015-present

1 to 2 1/2 day sessions of patients (depending on week)

Patients are scheduled for endocrinologist: Eugenio Cersosimo, MD, PhD

See independently 3-5 patients/ session, write note, and then check out to endocrinologist.

Preliminary PE performed and endo repeat, f/u with with interview, amendments and attestations by endocrinologist.

SERVICE TO GOVERNMENT:

<u>Dates</u>	<u>Type</u>	<u>Description</u>	<u>Role</u>
02/2013-01/2020	State Government	Texas Diabetes Council- DSHS, State of Texas	Vice Chair

Reappointed by Governor of Texas to serve second 6 year term and elected to serve as the Vice-Chair during this session. Appointments to TDC were delayed and asked to stay on as Vice-Chair until new appointees selected-served 7 years.

10/2007-02/2013	State Government	Texas Diabetes Council-DSHS, State of Texas	Secretary
-----------------	---------------------	--	-----------

*Appointed by Gov. Perry to Texas Diabetes Council, elected Secretary 10-07
Council is involved with preventing, improving the quality, and treating of Texans with and at risk of diabetes mellitus*

01/2006-01/2008	State Government	Texas Diabetes Council-Medical Advisory Committee	Interim Chair
-----------------	---------------------	--	---------------

Charged with algorithm development and standards of care for people with or at high risk of diabetes in the State of Texas

01/2002-01/2006	State Government	Texas Diabetes Council-Medical Advisory Committee	Vice Chair
-----------------	---------------------	--	------------

Advisory Subcommittee for Health Care Professionals Committee

01/2001-01/2018	State Government	Texas Diabetes Council-Healthcare Professionals Committee	Member
-----------------	---------------------	--	--------

Involved with development and overseeing algorithms for the proper treatment and prevention of diabetes mellitus, cardiovascular risks, complications, and education of Texans.

01/2001-01/2015	State Government	Texas Diabetes Council-Materials Dissemination and Distribution Committee	Member
-----------------	---------------------	---	--------

Charged with development and distribution of diabetes education tools available at no cost to those who request from the TDC

SERVICE TO THE INSTITUTION:

<u>Dates</u>	<u>Type</u>	<u>Description</u>	<u>Role</u>
2020-2022	School	CardioRenal Connections	Organizing Committee
8/2021	School	NPR: The Source- DM in San Antonio	Invited speaker
08/2020-08/2020	School	COVID-19 and Diabetes- SA Express	Invited speaker

News

Brief interview (virtual) about the pandemic and risks to DM patients

06/2020-06/2020	School	COVID-19 and Diabetes- The Current	Invited Participant
-----------------	--------	------------------------------------	---------------------

Interview to speak about COVID-19 and what we know for risks in diabetes

01/2020-01/2021	University	Cardiorenal Connections Conference- Organizing Committee	Organizing Committee Member
-----------------	------------	--	-----------------------------

On organizing committee for CRC meeting. Delayed but presented virtually in 1/2021

11/2017-11/2017	University	World Diabetes Day- Texas Diabetes Institute	Invited speaker
-----------------	------------	--	-----------------

Speech at TDI to staff/faculty

01/2006-Present	Hospital	University Health System, Subcommittee for Diabetes & Endocrinology	Member
-----------------	----------	---	--------

Member of Subcommittee to consider formulary status for medications for UHS, San Antonio, TX

SERVICE TO THE PROFESSION:

<u>Dates</u>	<u>Type</u>	<u>Description</u>	<u>Role</u>
01/2021-03/2021	National	ADA Reviewer of Abstracts for Annual Meeting	Reviewer

reviewer for abstracts for "Hormones other than insulin" both regular submission and late-breaking

01/2020-03/2020	National	ADA Reviewer of Abstracts for Annual Meeting	Reviewer
-----------------	----------	--	----------

Reviewer of GLP-1 abstracts

01/2019-01/2021	National	American Diabetes Association- Diabetes Self-Management and Education and Support, Professional Interest Group	Immediate Past Chair
-----------------	----------	--	----------------------

Past Chair of Professional Interest Group with over 5000 members. Charged with promoting DSMES activities, continuing education, sharing of questions, concerns, and ideas among members

01/2019-01/2020	National	New York Public Health Providers- Gouverneur Hospital, New York NY	Presenter
-----------------	----------	---	-----------

2, 1 day presentations on introduction to diabetes education principles, how to become a certified diabetes educator, how to treat DM and DM medications

01/2019-Present	International	Diabetes Spectrum Journal- Editor-In- Chief	Editor-in-Chief
-----------------	---------------	--	-----------------

Lead 8 HCP team of associate editors for peer-reviewed journal backed by the American Diabetes Association. Plan issues, review manuscripts submitted plus solicit invited manuscripts on selected topics.

Commitment: Review and read approximately 20-30 manuscripts a month and decide if they will be distributed to an AE for peer-review. Follow manuscripts through approval process, emails for revisions/ rejections, and final approval for publication of manuscripts.

Journal also publishes the speeches of American Diabetes Association Annual meeting Educator of Year, Behavior HCP of year, and President Healthcare and Education.

Diabetes Educator focused journal. ADA pays a partial salary support to UTHSA for my role.

01/2018-03/2019	National	ADARviewer of Abstracts for Annual Meeting	Reviewer
-----------------	----------	---	----------

Education abstracts reviewer for 2 years

06/2017-06/2017	National	American Diabetes Association Annual Scientific Sessions	Chair
-----------------	----------	---	-------

Chair- session on diabetes education and Continuous Glucose Monitoring. Extensive education on types available, difference of devices, educational principles, cost, and appropriate use.

06/2017-06/2017	National	American Diabetes Association Annual Scientific Sessions	Chair
-----------------	----------	---	-------

Chair- Diabetes Self-Management Education and Support Session at ADA Scientific Sessions

04/2017-04/2017	Local	Texas Public Radio-Interview	Speaker
-----------------	-------	------------------------------	---------

Interview on pre-diabetes and the risks to our San Antonio population

01/2017-01/2020	National	Diabetes Care- Manuscript Reviewer	Reviewer
<i>1-3 manuscripts reviewed per year</i>			
01/2017-01/2019	National	American Diabetes Association, Diabetes Self-Management Education and Support, Professional Interest Group	Chair
<i>Chair of Professional Interest Group with over 5000 members. Charged with promoting DSMES activities, continuing education, sharing of questions, concerns, and ideas among members</i>			
04/2016-04/2016	Local	Texas Public Radio-Interview	Speaker
<i>Interview about type 2 DM, reasons people develop, how to lower risk, how to effectively manage risk of complications</i>			
01/2016-01/2018	National	American Diabetes Association Co-Chair Education Subcommittee-National Annual Meeting	Co-Chair
<i>Co-Chair of the Education Committee charged with identification of topics and inviting speakers to present at the Annual Meeting</i>			
01/2016-01/2016	National	Georgia Public Health Providers	Presenter
<i>Introduction to Diabetes Education Principles as well as Introduction to Diabetes Medications and Treatment Given in Atlanta and Savannah, GA as 1 day seminars</i>			
01/2015-01/2016	National	American Diabetes Association Education Subcommittee- National Annual Meeting	Member
<i>On group that organized and invited speakers for Education Presentations for 2015 ADA National Annual Meeting</i>			
10/2013-10/2013	National	American Journal of Managed Care- Interview	Speaker
<i>Interview on Patient-Centered Diabetes Care in regards to medications</i>			
01/2013-Present	National	AADE in Practice (ADCES in Practice)	Editorial Board Member
<i>Quarterly clinically focused peer-reviewed journal published by the Association of Diabetes Care and Education Specialists.</i>			
01/2012-01/2017	National	Clinical Diabetes	Editorial Board Member
<i>Editorial Board Member for Quarterly Journal published by the American Diabetes Association</i>			
01/2010-01/2014	National	ISRN Endocrinology	Editorial Board Member

Online Journal

01/2007-01/2008

National

AADE in Practice

Editorial Board

			Member
		<i>editor and contributor- review about 2 manuscripts per month</i>	
01/2007-Present	National	Clinical Medicine Insights: Endocrinology and Diabetes	Editorial Board Member
		<i>Online Journal</i>	
01/2006-01/2012	National	Pharmacotherapy	Reviewer
		<i>Reviewer 2006, 2007, 2008, 2010, 2012</i>	
08/2003-08/2004	National	AADE-National Public Affairs Committee	Member
		<i>American Association of Diabetes Educators-Legislative and Social Agenda</i>	
08/2003-08/2004	National	AADE-Bookstore Selection Committee	Member
		<i>Help to select teaching and education aids to be offered in AADE bookstore</i>	
01/2003-01/2003	National	American Journal of Health-System Pharmacists	Reviewer
		<i>Reviewer-1 manuscript</i>	
01/2003-01/2003	National	AADE 2003 Annual Meeting Presentations	Reviewer
		<i>Review Insulin Resistance and Medication Abstracts</i>	
08/2002-02/2003	Local	ADA, South Texas District	Chair
		<i>Professional Education Symposium, American Diabetes Association</i>	
01/2002-01/2003	National	National Certification Board for Diabetes Educators, Item Writing Committee	Member
		<i>Item Writing for National Certification Test for Candidates for the Certified Diabetes Educator Test</i>	
01/2001-01/2002	State	TSHP Journal	Editorial Board Member
		<i>TSHP Journal, Journal of the Texas Society of Health-System Pharmacists. Peer-reviewed journal.</i>	
09/1997-Present	National	Consultant- PharmD Colleagues	Consultant
		<i>Over years frequently contacted by colleagues around country for "curbside consults" on difficult patients. This includes locally: UT Primary Care, UHS transplant, UHS inpatient service, HEB pharmacists, independent pharmacist groups (at time named Amerisource pharmacy Group), Incarnate Word College of Pharmacy State: Dallas based pharmacists, Texas "valley" based pharmacists, El Paso based</i>	

pharmacists
National: Midwestern University, Butler University

SERVICE TO THE PUBLIC:

<u>Dates</u>	<u>Type</u>	<u>Description</u>	<u>Role</u>
07/2017-Present	Community	San Antonio Health Advisory Board-Diabetes Workgroup	Member
<i>Concerned with networking of resources available for organizations, health-systems, families, and patients with diabetes</i>			
01/2015-01/2017	Patient Care Community	American Diabetes Association South Texas Chapter	Immediate Past President
<i>As Immediate Past-President, help with current President to make tenure successful.</i>			
01/2013-01/2015	Patient Care Community	American Diabetes Association, South Texas Chapter	President
<i>Oversee Leadership Board and help to coordinate programs, outreach, and other aspects for S. Texas Chapter. Attend all meetings (2 times/month) and help with coordination of large public fund-raising events. Speak at events as needed and help to contact organizations, corporations, and businesses that may support the American Diabetes Association mission.</i>			
01/2011-01/2017	Community	American Diabetes Association, South Texas Community Leadership Board	Board Member
<i>Serve on Community Leadership Board and as Mission Delivery Chair for ADA, South Texas to further the mission of the American Diabetes Association.</i>			
01/2005-01/2015	Health Education	Texas Diabetes Institute-ADA DM Education Recognition Committee	Advisory Committee Member
<i>Help with Community understanding of needs assessment for Texas Diabetes Institute DM Education program</i>			
01/2002-01/2002	Community	American Diabetes Association-Diabetes EXPO	Chair
<i>Programs Chairman</i>			
01/1999-01/2003	Patient Care		

C

o

mmunity

Texas Migrant Council- Health
Committee

Member

National organization looking after migrant health across states

PROFESSIONAL AFFILIATIONS:**Dates****Organization**

06/2000-Present

American Diabetes Association

01/2000-01/2001

Central Texas Society of Health System Pharmacists

Additional Details: Treasurer 2000-2001

01/1995-Present

American Association of Diabetes Educators, also known as
Association of Diabetes Care and Education Specialists

01/1994-12/2000

American College of Clinical Pharmacy